Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stephen P. Balk"'
Autor:
Yi-Mi Wu, Glenn C. Gaviola, Massimo Loda, Scott A. Tomlins, Raquel Perez-Lopez, Bruce Montgomery, Himisha Beltran, Jeremy C. Durack, Mary-Ellen Taplin, Michael J. Morris, David Smith, Charles L. Sawyers, Arul M. Chinnaiyan, Penny Flohr, Anuradha Gopalan, Howard I. Scher, Christine Brennan, Carrie Sougnez, Scott T. Tagawa, Roberta Ferraldeschi, Rohit Mehra, Stephen P. Balk, Manaswi Gupta, Eliezer M. Van Allen, Philip W. Kantoff, Rosina T. Lis, Evan Y. Yu, Jianjiong Gao, Kenneth J. Pienta, Xuhong Cao, Joaquin Mateo, Johann S. de Bono, Maha Hussain, Olivier Elemento, Stephen B. Solomon, Zafeiris Zafeiriou, Robert J. Lonigro, Wassim Abida, Hyojeong Mulcahy, Jake Vinson, Gerhardt Attard, Andrea Sboner, Nina Tunariu, Javed Siddiqui, Yu Chen, Michaela Bowden, Colin C. Pritchard, Lakshmi P. Kunju, Susana Miranda, Lawrence D. True, Felix Y. Feng, Heather H. Cheng, Kathleen A. Cooney, Peter S. Nelson, Francesca Demichelis, Pankaj Vats, Dan R. Robinson, Brian D. Robinson, Marc H. Schiffman, Mark A. Rubin, Kenneth Eng, Juan Miguel Mosquera, Stephen R. Plymate, Elahe A. Mostaghel, Robert K. Bradley, Alexandros Sigaras, Elisabeth I. Heath, Nikolaus Schultz, Heidi Dvinge, Victor E. Reuter, Dana E. Rathkopf, Levi A. Garraway, David M. Nanus
Publikováno v:
Cell. 161:1215-1228
SummaryToward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295f6e5ec4b1b918591eefcf24e8e7ac
https://doi.org/10.1016/j.cell.2015.05.001
https://doi.org/10.1016/j.cell.2015.05.001
Autor:
Peter S. Nelson, Brett T. Marck, Stephen P. Balk, Stephen R. Plymate, R. Bruce Montgomery, Elahe A. Mostaghel, Alvin M. Matsumoto, Robert L. Vessella
Publikováno v:
Clinical Cancer Research. 17:5913-5925
Purpose: Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and suppresses tumor growth in patients with castration-resistant prostate cancer (CRPC). The effectiveness of abiraterone in reducing tumor androgens is not known, nor ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2df851976213bec418c29cca715510
https://doi.org/10.1158/1078-0432.ccr-11-0728
https://doi.org/10.1158/1078-0432.ccr-11-0728
Autor:
Eva Corey, Stephen R. Plymate, Elahe A. Mostaghel, Osama S Mohammad, Peter S. Nelson, Michael D. Nyquist, Michael T. Schweizer, Stephen P. Balk
Publikováno v:
Cancers
Cancers, Vol 9, Iss 12, p 166 (2017)
Cancers, Vol 9, Iss 12, p 166 (2017)
Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression of systemic testosterone (T) has remained the most effective initial therapy for advanced disease although progression inevitably occurs. From the inception of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a4c6c158a66d6b397468615ba6d53ad
https://doi.org/10.3390/cancers9120166
https://doi.org/10.3390/cancers9120166
Autor:
Dan Robinson, Eliezer M. Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J. Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C. Pritchard, Gerhardt Attard, Himisha Beltran, Wassim Abida, Robert K. Bradley, Jake Vinson, Xuhong Cao, Pankaj Vats, Lakshmi P. Kunju, Maha Hussain, Felix Y. Feng, Scott A. Tomlins, Kathleen A. Cooney, David C. Smith, Christine Brennan, Javed Siddiqui, Rohit Mehra, Yu Chen, Dana E. Rathkopf, Michael J. Morris, Stephen B. Solomon, Jeremy C. Durack, Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen P. Balk, Glenn Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquin Mateo, Raquel Perez-Lopez, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth W. Eng, Olivier Elemento, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan
Publikováno v:
Cell. 162(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f341b44296fb9722b11a7177b55d02e0
Autor:
Martin G. Sanda, Michael Nowak, M. Simo Arredouani, Stephen P Balk, Mark A. Exley, Petr Ilyinski
Publikováno v:
The FASEB Journal. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb9d50ab58ffbd50817871244ab3b95b
https://doi.org/10.1096/fasebj.22.1_supplement.1077.23
https://doi.org/10.1096/fasebj.22.1_supplement.1077.23
Autor:
Stephen P. Balk, Jing Ma, Glenn J. Bubley, Michael Pollak, Meir J. Stampfer, J. Michael Gaziano, Haojie Li
Publikováno v:
The Prostate. 67(12)
BACKGROUND. The Hypoxia-inducible factor-1 (HIF-1) plays an important role in regulating angiogenesis in response to hypoxia. Two non-synonymous polymorphisms (P582S C!T and A588T G!A) in the coding region of the subunit 1a (HIF-1a) gene have been as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd911603bf54e47d94fac1abae1dc64
https://pubmed.ncbi.nlm.nih.gov/17624927
https://pubmed.ncbi.nlm.nih.gov/17624927